Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Must-Have Cooking Machine in Your Kitchen- 2023's Best 10 Cell phone Advancements You Can't Miss
- What to know about King Charles III's cancer treatment and his message to the public
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- Figure out How to Back Your Rooftop Substitution
- What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say.
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- Step by step instructions to Choose the Right Internet based Degree Program for Your Future
- Find Unexpected, yet invaluable treasure Excursion Rentals
